Bavencio (avelumab)

pCPA File Number: 21433

Negotiation Status:

Concluded with an LOI

Indication(s):

Indicated for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy

Sponsor/Manufacturer:

EMD Serono a Division of EMD Inc. Canada

CADTH Project Number:

PC0225

pCPA Engagement Letter Issued:

2021-07-22

Negotiation Process Concluded:

2021-12-15